Locations
Waltham, MA, USA
industry
Biotechnology · DeepTech · Health
Size
51-200 employees
Stage
Series B
founded in
2015
Arrakis Therapeutics is pioneering a new class of genetic medicines known as RNA-targeted small molecules (r SMs). The company aims to revolutionize drug discovery by targeting RNA biology, which has the potential to unlock hundreds of biological targets currently inaccessible to traditional genetic medicine. With a robust technology platform and a growing pipeline of proprietary and partnered r SM medicines, Arrakis is positioned to deliver innovative oral therapies for patients suffering from various diseases, including neurology and oncology. Their collaborative and fearless team is dedicated to pushing the boundaries of drug discovery, making significant strides towards impactful therapies for patients.
Something looks off?